WINDTREE THERAPEUTICS INC. overview

Windtree Receives Notice of Delisting from NASDAQ - Common Stock to Begin Trading on OTCQB® Market Effective May 5, 2017 - PR Newswire WARRINGTON, Pa., May 3, 2017 WARRINGTON, Pa. , May 3, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has received written notification from the NASDAQ Stock Market ("NASDAQ") that it has determined to delist the...

Windtree Announces Successful Completion of Second and Final AEROSURF® Phase 2b Clinical Trial Interim Safety Review -DSMB Recommends Continued Enrollment in AEROSURF Phase 2b Clinical Trial Without Modifications- -Company Remains on Track to Release Phase 2b Results Mid-Year 2017- PR Newswire WARRINGTON, Pa., April 11, 2017 WARRINGTON, Pa. , April 11, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant...

Windtree Therapeutics Reports Fourth Quarter 2016 Financial Results and Provides Key Business Updates Company Continues to Advance Phase 2 Program and is On-Track for Mid-Year Phase 2b Results PR Newswire WARRINGTON, Pa., March 31, 2017 WARRINGTON, Pa. , March 31, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported financial results for the fourth quarter ended...

Windtree Therapeutics' Aerosolized KL4 Surfactant Reduces Lung Inflammation and Improves Survival in a High-Pathogen Avian Influenza Preclinical Study PR Newswire WARRINGTON, Pa., Feb. 16, 2017 WARRINGTON, Pa. , Feb. 16, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focusing on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced today that data from a preclinical influenza study showed that aerosolized KL4 surfactant...

Windtree Therapeutics Completes $10.5 Million Private Offering Company Now Adequately Funded Through AEROSURF® Phase 2b Data in Mid-2017 PR Newswire WARRINGTON, Pa., Feb. 15, 2017 WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has completed a $10.5 million private placement of convertible preferred stock units and now...

Windtree Therapeutics to Host a Conference Call and Webcast at 8:00 AM on Thursday, February 16, 2017 to Provide Clinical and Financial Updates PR Newswire WARRINGTON, Pa., Feb. 15, 2017 WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will host a conference call and webcast (including a slide presentation) at 8:00 AM EST on Thursday, February...